<DOC>
	<DOCNO>NCT00287989</DOCNO>
	<brief_summary>RATIONALE : Erlotinib may stop growth tumor cell block enzymes need cell growth . Drugs use chemotherapy , paclitaxel carboplatin , work different way stop growth tumor cell , either kill cell stop divide . Giving erlotinib together paclitaxel carboplatin may kill tumor cell . PURPOSE : This randomized phase II trial study two different dos erlotinib give together paclitaxel carboplatin compare well work treat patient stage III , stage IV , recurrent non-small cell lung cancer .</brief_summary>
	<brief_title>Erlotinib , Paclitaxel , Carboplatin Treating Patients With Stage III , Stage IV , Recurrent Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Compare major objective response ( complete partial response ) rate patient stage IIIB IV recurrent non-small cell lung cancer treat high- versus low-dose erlotinib hydrochloride combine paclitaxel carboplatin . - Compare duration response , time progression , survival patient treat regimen . - Characterize compare toxicity regimens . - Determine recommend phase III dose erlotinib hydrochloride . OUTLINE : This randomize , open-label , multicenter study . Patients stratify accord gender . Patients randomize 1 2 treatment arm . - Arm I : Patients receive oral high-dose erlotinib hydrochloride day 1 2 . Patients also receive paclitaxel IV 3 hour follow carboplatin IV 30 minute day 3 . - Arm II : Patients receive oral low-dose erlotinib hydrochloride , paclitaxel , carboplatin arm I . In arm , treatment repeat every 21 day 6 course absence disease progression unacceptable toxicity . After completion study treatment , patient follow periodically . PROJECTED ACCRUAL : A total 58 patient accrue study .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Pathologically confirm nonsmall cell lung cancer Stage IIIB IV recurrent disease Measurable evaluable indicator lesion Must smoke ≥ 100 cigarette his/her lifetime PATIENT CHARACTERISTICS : Karnofsky performance status 70100 % WBC ≥ 4,000/mm^3 Platelet count ≥ 100,000/mm^3 Creatinine ≤ 1.5 mg/dL OR creatinine clearance ≥ 50 mL/min Bilirubin ≤ 1.0 mg/dL AST ≤ 2.5 time upper limit normal ( ULN ) Alkaline phosphatase ≤ 2.5 time ULN Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception ≥ 1 week completion study treatment No gastrointestinal tract disease inability take oral medication No prior malignancy within past 2 year except nonmelanoma skin cancer carcinoma situ cervix No active medical problem , include severe infection , unstable angina , myocardial infarction within past 6 month No poorly control hypertension severe malnutrition No New York Heart Association class III IV congestive heart failure serious cardiac arrhythmia require medication except chronic atrial arrhythmia ( i.e. , atrial fibrillation paroxysmal supraventricular tachycardia ) PRIOR CONCURRENT THERAPY : At least 3 week since prior radiotherapy major bone marrowcontaining sit No prior chemotherapy advance nonsmall cell lung cancer No prior agent direct epidermal growth factor receptor ( EGFR ) /HER axis ( e.g. , gefitinib , cetuximab , trastuzumab [ Herceptin® ] ) No prior surgical procedure result abnormal absorption oral medication No concurrent surgical resection , palliative radiotherapy , hormonal therapy No concurrent anticancer therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>recurrent non-small cell lung cancer</keyword>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
	<keyword>stage IV non-small cell lung cancer</keyword>
</DOC>